Navigation Links
Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials

ivision of Cardiology at the Tufts-New England Medical Center, and professor of Medicine at Tufts University School of Medicine, Boston, Mass. Konstam presented the short- and long-term EVEREST data analyses during a late-breaker session Sunday, March 25 at the ACC. "In the long-term trial, tolvaptan neither statistically improved nor worsened survival relative to placebo. The EVEREST data suggest that tolvaptan may be a potential therapy for patients with heart failure."

Tolvaptan is a novel, investigational small molecule designed to be an antagonist of the vasopressin V2 receptor, which plays a role in the kidney's regulation of fluid excretion. The majority of patients hospitalized for ADHF, the worsening of chronic HF that affects 1 million U.S. residents annually,(3) have edema or excess body fluid, which is treated with diuretics to excrete the fluid. In contrast to diuretics, tolvaptan is designed to promote aquaresis, the excretion of electrolyte-free water.(1) Otsuka Pharmaceutical Co., Ltd. (Japan) and Otsuka Pharmaceutical Development & Commercialization, Inc., are developing tolvaptan, which has the potential to be the first available oral vasopressin receptor antagonist.(4,5)

Short-Term Studies: Pre-Specified Secondary Endpoints

In the two short-term studies, reductions in average body weight at day seven or discharge were statistically significantly different between the tolvaptan group versus the placebo group, 3.35 kilograms (kg) and 2.73 kg, respectively, in study A (p less than 0.001) and 3.77 kg and 2.79 kg, respectively, in study B (p less than 0.001). In addition, the use of tolvaptan significantly reduced patients' body weight as early as on the first day of treatment in both short-term studies (p less than 0.001).(1) There was no significant difference between the treatment groups in improvement in patient-assessed global clinical status at day 7 or discharge, if earlier; however the changes were numerically in favor
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
7. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
8. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
10. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
11. UCB Presents Long-Term CImzia Data in Crohns Disease
Post Your Comments:
(Date:8/31/2015)... , August 31, 2015 ... (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"), ... biomedical innovations in ophthalmology and cancer diagnostics, today ... (TASE: MCTC), has identified several new genetic markers ... jawbone in patients treated with bisphosphonate drugs and ...
(Date:8/31/2015)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... has completed enrollment of the additional subjects, as ... this year, into the company,s Phase 2 study ... regulator (IDR) and is being evaluated as a ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
Breaking Medicine Technology:BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... 12, 2011  Public Relations tactics and tools are ... makes Public Relations a highly leveraged marketing investment, ... More specifically, Public Relations tools can be easily ... lifecycle, especially at launch and brand-building years. ...
...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) will be presenting ... 30th Annual J.P. Morgan Healthcare Conference on Monday, January 9, ... at 4:00 PM (Pacific). Interested parties may ... Annual J.P. Morgan Healthcare Conference over the Internet available at ...
Cached Medicine Technology:Utilizing Public Relation Strategies During Pharmaceutical Lifecycle Management for Greatest Impact on Brand and Consumer Base 2
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... urgent care and accessible primary care, is enhancing its existing presence in Tennessee ... in Knoxville. The location is the company’s second in Knoxville, sixteenth in Tennessee, ...
(Date:8/31/2015)... KY (PRWEB) , ... August 31, 2015 , ... ... Wyoming, has selected ezDI’s computer-assisted coding (CAC) software for its Clinical Documentation Improvement ... engine, ezNLP, and a patent pending ICD-10 solution - ezCAC is an enterprise-level ...
(Date:8/31/2015)... ... ... The more hours young adults spend watching television each day, the greater ... a 15-year analysis by the University of Pittsburgh Graduate School of Public Health revealed. ... adulthood is an important time to intervene and promote less television viewing, according to ...
(Date:8/31/2015)... PA (PRWEB) , ... August 31, 2015 , ... ... than their peers may be at a greater risk for injury, potentially because ... behaviors, a University of Pittsburgh Graduate School of Public Health analysis discovered. ...
(Date:8/31/2015)... ... 2015 , ... With baseball season in full swing, many fans are already ... sports world. Fans desire nothing more than to see their favorite team take the ... those who are too young to really understand what all the fuss is about, ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Watching More TV as a Young Adult Predicts Obesity 2Health News:Watching More TV as a Young Adult Predicts Obesity 3Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2
... 15 million Americans are recruited annually to participate in clinical ... and most will be compensated for their participation. ... compensation for time and expenses; not as compensation for potential ... new study finds that volunteers have a very different view ...
... leads to success, study finds , FRIDAY, Dec. 4 ... self-weighing are among the most effective weight control strategies ... 130 adolescents about their weight-control strategies and lifestyle habits. ... not. The responses were grouped into four categories: , ...
... and surveillance urged for at-risk patient groups , FRIDAY, ... Ewing sarcomas and central nervous system tumors, carry the ... The study authors analyzed data from 12,795 five-year survivors ... in the Childhood Cancer Survivor Study. , The researchers ...
... take breast cancer drug, study finds , FRIDAY, Dec. 4 ... reason why only 6 percent of American women at high ... tamoxifen to prevent the disease, a new study finds. , ... benefits of tamoxifen, researchers at the University of Michigan Comprehensive ...
... , JACKSONVILLE, Fla., ... awards for their work in improving the health of Florida,s ... Florida,s 2009 Sapphire Award ceremony. , The Sapphire Award is ... have demonstrated excellence in addressing health disparities within their communities. ...
... , PARAMUS, N.J., Dec. 4 Movado Group Inc. (NYSE: ... Jewelers, Atlanta, Georgia, shared in a tribute on December 3, ... her stellar performance in the tournament. Melanie became the youngest ... http://www.newscom.com/cgi-bin/prnh/20091204/NY21184 ) , At a celebratory reception held ...
Cached Medicine News:Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Top Nonprofits Honored for Improving Health of Floridians 2Health News:Top Nonprofits Honored for Improving Health of Floridians 3
... pressure sensor and continues to lead ... only sensor on the market that ... significantly improved maneuverability and pushability, it ... as well as a valuable clinical ...
... its professional AED offeringthe G3 Pro. ... ECG color display, provides manual override ... most advanced technology available to provide ... for emergency treatment of sudden cardiac ...
... The Littmann Electronic Stethoscope Model 4100WS features ... technology allowing you to reduce ambient noise ... eliminating critical body sounds. Three frequency modes ... and other body sounds: Bell (20-200 Hz), ...
... is a 3D quantitative echo system ... exams are performed. Intelligent design and ... revolutionary clinical performance and workflow. The ... data streams simultaneously and incorporates a ...
Medicine Products: